Literature DB >> 8960893

Familial risk and colorectal cancer.

R W Burt1.   

Abstract

Familial risk of colon cancer is common. The rare syndromes of FAP and HNPCC account for a small fraction of familial cases. A working knowledge of these syndromes is important, however, because appropriate management can prevent most cases of colon cancer in families with these conditions. Furthermore, the genes that give rise to FAP and HNPCC have been identified, and genetic testing to find gene carriers in affected families is now commercially available. In addition to the syndromes, colon cancer commonly clusters in families. The risk of colon cancer is two to threefold increased when a first-degree relative is affected with this malignancy. The risk is further increased if multiple first-degree relatives have colon cancer or if a diagnosis in a relative is made at an age of 50 years or younger. The genetic causes of this more commonly observed of familial clustering have not been clarified, but screening based on the degree of familial risk has been suggested.

Entities:  

Mesh:

Year:  1996        PMID: 8960893     DOI: 10.1016/s0889-8553(05)70275-2

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  3 in total

1.  Assay validation for identification of hereditary nonpolyposis colon cancer-causing mutations in mismatch repair genes MLH1, MSH2, and MSH6.

Authors:  Madhuri Hegde; Maria Blazo; Belinda Chong; Tom Prior; Carolyn Richards
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

Review 2.  Environmental influences on the high mortality from colorectal cancer in African Americans.

Authors:  Sumit Sharma; Stephen J D O'Keefe
Journal:  Postgrad Med J       Date:  2007-09       Impact factor: 2.401

3.  Late outcomes of colorectal cancer treatment: a FECS-EUROCARE study.

Authors:  Gemma Gatta; Laura Ciccolallo; Jean Faivre; Anne-Marie Bouvier; Franco Berrino; Jean Pierre Gerard
Journal:  J Cancer Surviv       Date:  2007-09-27       Impact factor: 4.442

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.